Apellis Pharmaceuticals, Inc.

This study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage, compared to a placebo. Participants received injections twice a week …

This study tested whether a prefilled syringe makes it safer and easier to give pegcetacoplan injections for geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. Forty-four adults aged 60 and older received the injection in one eye. The…

This study looked at the long-term safety and effectiveness of a drug called pegcetacoplan for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes vision loss. About 792 participants who had already been in earlier studies received the…

This study tested a drug called pegcetacoplan in 13 adults whose rare kidney disease (C3G or IC-MPGN) came back after a kidney transplant. The goal was to see if the drug could safely reduce signs of disease in kidney tissue. Participants received the drug or standard care, and r…